Introduction

Two medications are racing toward FDA approval with weight loss results that surpass anything currently available. Retatrutide (Eli Lilly) and CagriSema (Novo Nordisk) represent different approaches to the same goal: achieving weight loss approaching bariatric surgery without the scalpel.

TRIUMPH-4 showed retatrutide achieving 28.7% weight loss at 68 weeks in December 2025. Six months earlier, REDEFINE-1 showed CagriSema achieving 20.4% weight loss at the same timepoint. Both substantially outperform semaglutide's 14.9%. As of August 2026, retatrutide has completed all four core Phase 3 trials — including TRIUMPH-2 (obesity + diabetes) and TRIUMPH-3 (obesity + cardiovascular disease), both confirmed July 23, 2026. CagriSema retains a filing head start, having submitted for FDA review in December 2025.

The difference? Mechanism and magnitude. Retatrutide is a single molecule activating three hormone receptors (GLP-1, GIP, glucagon). CagriSema is two separate molecules — semaglutide (GLP-1 agonist) plus cagrilintide (amylin analog) — combined in one injection. One produces roughly 8 percentage points more weight loss. The other reached the FDA first.

This comparison examines mechanisms, efficacy data, side effects, approval timelines, and which medication will dominate when both reach market.

The Mechanisms: Triple Agonist vs Dual Combination

Retatrutide: Single Molecule, Three Receptors

Retatrutide is a tri-agonist — one engineered molecule that simultaneously activates three distinct hormone pathways.

GLP-1 Receptor Activation:

• Suppresses appetite through hypothalamic pathways
• Slows gastric emptying
• Enhances insulin secretion

GIP Receptor Activation:

• Amplifies GLP-1 satiety effects
• Improves insulin sensitivity
• May directly affect fat cell metabolism

Glucagon Receptor Activation:

• Increases energy expenditure (metabolic rate)
• Promotes fat breakdown (lipolysis)
• May prevent metabolic adaptation

The Advantage: Single molecule means simpler manufacturing, potentially easier regulatory approval, and all three pathways activated with every dose.

CagriSema: Two Molecules, Complementary Mechanisms

CagriSema combines two existing molecules in a fixed-dose injection.

Semaglutide 2.4mg (GLP-1 Agonist):

• Proven GLP-1 effects (appetite suppression, gastric emptying)
• Already FDA-approved as Wegovy
• Established safety profile

Cagrilintide 2.4mg (Amylin Analog):

• Mimics amylin, a hormone co-secreted with insulin
• Slows gastric emptying through different pathway than GLP-1
• Reduces appetite through hindbrain (not hypothalamus)
• Improves postprandial glucose

The Advantage: Leverages proven semaglutide efficacy and safety, adds complementary amylin effects. If approved, becomes first GLP-1/amylin combination.

Weight Loss Efficacy: Head-to-Head Comparison

Primary Phase 3 Results

Key Finding: Retatrutide produces 8.3 percentage points more weight loss than CagriSema at 68 weeks.

Real-World Translation

For a 250-pound person:

*Assuming 5'10" height

Difference: Retatrutide loses 21 more pounds than CagriSema.

Percentage Achieving Weight Loss Thresholds

Key Finding: Both medications get most patients past 20% loss. Retatrutide pushes more patients to 25%+.

Trial Design Considerations

REDEFINE-1 Used Flexible Dosing: Investigators could reduce dose if patients experienced intolerable side effects. Only 57% of participants reached the highest 2.4mg/2.4mg dose. This may have reduced average weight loss.

On-Treatment Analysis (If Everyone Stayed on Max Dose): CagriSema achieved 22.7% weight loss using trial-product estimand (assumes perfect adherence at max dose).

TRIUMPH-4 Used Fixed Dosing: All patients in the 12mg group reached 12mg unless they discontinued. This may produce higher average but lower real-world applicability.

Verdict: Direct comparison difficult due to different trial designs, but retatrutide's advantage appears substantial even accounting for flexible vs fixed dosing.

Side Effect Profiles

Gastrointestinal Side Effects

Key Finding: CagriSema had highest overall GI event rate (79.6%). Most were mild-moderate and transient.

Dysesthesia: Retatrutide's Unique Issue

Dysesthesia (abnormal touch sensations) affects roughly 1 in 5 retatrutide patients at the highest dose in TRIUMPH-4, and about 1 in 8 in TRIUMPH-1. This side effect doesn't occur with CagriSema or semaglutide. For a deeper look, see our complete dysesthesia guide.

Discontinuation Rates

Retatrutide's TRIUMPH-1 rate (11.3%, general obesity population) is a meaningful improvement over TRIUMPH-4's 18.2% (osteoarthritis population), though still higher than semaglutide (6.9%). CagriSema's rate of approximately 6% is comparable to semaglutide, reflecting its established semaglutide component.

Approval Timeline and Availability

CagriSema: Ahead in the Race

FDA Submission: December 18, 2025 (NDA filed)
‍Expected FDA Decision: Q4 2026 or Q1 2027
‍Predicted Launch: Mid-2027

Advantage: A filing head start of roughly a year over retatrutide's expected Q1 2027 BLA. How much of that translates into an earlier launch depends on which FDA review track retatrutide gets — see below.

REDEFINE Program Status:

• REDEFINE-1: ✅ Complete (obesity, 20.4% weight loss)
• REDEFINE-2: ✅ Complete (type 2 diabetes, 13.7% weight loss)
• REDEFINE-3: Ongoing (cardiovascular outcomes trial)
• REDEFINE-8: Ongoing (body composition study)
• High-dose CagriSema (2.4/7.2mg): Starting late 2026

Retatrutide: All Core Trials Complete

BLA Submission: Expected Q1 2027 (Biologics License Application — not an NDA, since retatrutide is a biologic)
‍Expected FDA Decision: Q3 2027 (priority review) to Q1–Q2 2028 (standard review)
‍Predicted Launch: Late 2027 to mid-2028

TRIUMPH Program Status:

• TRIUMPH-4: ✅ Complete (osteoarthritis, 28.7% weight loss)
• TRIUMPH-1: ✅ Complete — 28.3% weight loss (May 2026)
• TRIUMPH-2: ✅ Complete — 20.8% weight loss (obesity + type 2 diabetes, July 23, 2026)
• TRIUMPH-3: ✅ Complete — 22.6% weight loss (obesity + cardiovascular disease, July 23, 2026)
• TRIUMPH-6: Weight maintenance trial (ongoing, not required for initial approval)

Status: All four core registrational trials are now complete — the data package is done. Whether the FDA grants priority review is not yet determined; the timeline above reflects both scenarios. For the full breakdown, see our complete FDA approval timeline guide.

The gap has narrowed. CagriSema still holds a filing-date head start of about a year, but under a priority-review scenario for retatrutide (Q3 2027 decision), the launch windows could end up close together — both landing somewhere in the second half of 2027. Under standard review for retatrutide, CagriSema's lead widens back out to roughly a year.

Predicted Pricing and Insurance Coverage

Expected Monthly Costs

Both will be expensive. CagriSema may price slightly higher as an "evolution of Wegovy" from Novo Nordisk's established franchise. For a full breakdown of retatrutide cost expectations and insurance strategies, see our complete cost guide.

Insurance Coverage Predictions

CagriSema (Advantage: Semaglutide Component):

• Leverages Wegovy's established coverage
• "Combination of proven medication + new molecule" — easier sell to insurers
• Predicted coverage: 50-60% of commercial plans initially

Retatrutide (Challenge: Novel Molecule, Now With a Broader Data Package):

• Entirely new drug class, no established coverage precedent
• Higher efficacy, but also a broader side-effect profile
• Will likely require trial-and-failure of cheaper options
• Now backed by efficacy data across obesity, diabetes, and cardiovascular populations (TRIUMPH-1/2/3/4), which may support broader indication requests over time
• Predicted coverage: 40-50% of commercial plans initially

Clinical Trial Populations and Indications

CagriSema: Diabetes Focus

REDEFINE-1: Obesity without diabetes (3,417 participants)
REDEFINE-2: Obesity WITH type 2 diabetes (1,206 participants) — 13.7% weight loss
‍REIMAGINE Program: Additional diabetes-focused trials

Advantage: Diabetes data reported first (REDEFINE-2), positioning CagriSema for dual obesity + diabetes indications, like tirzepatide (Mounjaro/Zepbound).

Retatrutide: Complication Focus

TRIUMPH-4: Obesity + knee osteoarthritis (445 participants) — 28.7% weight loss
‍TRIUMPH-2: Obesity + type 2 diabetes (1,152 participants) — 20.8% weight loss, up to 1.6 percentage points HbA1c reduction
‍TRIUMPH-3: Obesity + cardiovascular disease (1,949 participants) — 22.6% weight loss
‍TRIUMPH-6: Weight maintenance trial (ongoing)

Advantage: Multiple complication-specific trials — now including completed diabetes (TRIUMPH-2) and cardiovascular (TRIUMPH-3) data — position retatrutide for a broader label than CagriSema currently has evidence for (obesity + OA + diabetes + cardiovascular disease, and possibly OSA). CagriSema's diabetes-data head start (REDEFINE-2 reported before TRIUMPH-2) has narrowed now that both companies have completed diabetes-population trials.

Manufacturing and Supply

CagriSema: Combination Product Challenge

Complexity: Two separate molecules in one injection requires complex formulation. Fixed-dose combination means less flexibility in dosing.

Novo Nordisk Experience: Company has struggled with semaglutide supply shortages (Wegovy, Ozempic). Will CagriSema face the same issues?

Retatrutide: Single Molecule Advantage

Simplicity: One molecule, potentially simpler manufacturing and quality control.

Eli Lilly Investment: $9 billion in new US manufacturing facilities specifically for obesity medications.

Prediction: Both will face supply constraints at launch, but retatrutide's single-molecule structure may scale faster.

Which Medication Will Win?

CagriSema's Advantages:

✅ Filing Head Start: Submitted December 2025, roughly a year ahead of retatrutide's expected BLA
✅ Leverages Wegovy Success: Built-in brand recognition
✅ Proven Semaglutide Component: Half the drug is already approved
✅ Diabetes Data Reported First: REDEFINE-2 completed before TRIUMPH-2, though the gap has narrowed
✅ No Dysesthesia: Cleaner safety profile in one key area

Retatrutide's Advantages:

✅ Higher Efficacy: 28.7% vs 20.4% (8.3 points more)
✅ Superior BP Reduction: -14 mmHg vs likely similar to semaglutide
✅ Single Molecule: Potentially easier manufacturing
✅ Complete Trial Program: All four core trials done, spanning obesity, osteoarthritis, diabetes, and cardiovascular populations
✅ Novel Class: First triple agonist = strong IP protection

The Verdict: Market Will Support Both

These medications won't compete head-to-head. They'll serve different niches:

CagriSema Will Likely Reach Patients First:

• Patients familiar with the Wegovy brand
• Those wanting a proven semaglutide component
• People with type 2 diabetes (REDEFINE-2 data available first)
• Earlier availability (mid-2027, versus retatrutide's late 2027 to mid-2028 window)

Retatrutide Will Likely Dominate on Efficacy:

• Patients needing maximum weight loss (BMI ≥40)
• Those with multiple complications (OA + obesity, or diabetes, or cardiovascular disease)
• People who plateaued on CagriSema or other GLP-1 medications
• Patients willing to wait for the highest efficacy

Tirzepatide (Zepbound) Will Remain Relevant:

• Already available NOW
• Proven safety with 22.5% weight loss
• Lower cost than either new option
• Established insurance coverage

For a full three-way comparison including tirzepatide and semaglutide, see our complete comparison guide.

The High-Dose CagriSema Wildcard

Novo Nordisk announced plans for CagriSema 2.4mg/7.2mg trials starting late 2026 — tripling the cagrilintide dose.

Potential Impact: If 2.4mg/2.4mg achieves 20.4% weight loss, could 2.4mg/7.2mg achieve 25-27%? That would narrow the gap with retatrutide substantially.

Risk: Higher cagrilintide dose will likely increase GI side effects and discontinuation rates. May not be tolerable enough for widespread use.

Timeline: High-dose results won't be available until 2028+, well after standard-dose approval. This is a second-generation product.

Conclusion

Retatrutide and CagriSema represent the next generation of obesity pharmacotherapy. Both substantially outperform currently available medications. As of August 2026, both have completed their core efficacy trial programs — CagriSema's REDEFINE-1/2 and retatrutide's TRIUMPH-1/2/3/4 — though CagriSema retains a filing-date head start, having submitted in December 2025 versus retatrutide's expected Q1 2027 BLA.

The 8.3 percentage point efficacy advantage for retatrutide is meaningful — 21 pounds of difference for a 250-pound person. But CagriSema's head start, proven semaglutide component, and earlier diabetes data position it well to reach patients first, likely by mid-2027. Retatrutide's realistic window is late 2027 to mid-2028, depending on whether the FDA grants priority review.

Most patients with severe obesity (BMI ≥40) will likely wait for retatrutide's superior efficacy. Patients with BMI 30-40 may prefer CagriSema's earlier availability. The market is large enough to support both medications profitably.

The real question: will either medication achieve the sustained, widespread use needed to address the global obesity epidemic? Or will high costs, insurance restrictions, side effect burdens, and supply constraints limit them to a small fraction of eligible patients?

Sources

• Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. NEJM 2025 (REDEFINE-1)
• Davies MJ, et al. Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. NEJM 2025 (REDEFINE-2)
• Novo Nordisk FDA NDA submission announcement (December 18, 2025)
• Eli Lilly press release: TRIUMPH-4 Phase 3 Trial Results. December 2025.
• Eli Lilly press release: TRIUMPH-1 Phase 3 topline results. May 21, 2026.
• Eli Lilly press release: Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials. July 23, 2026.